AR113803A1 - Compuesto de pirimidina como inhibidor de jak quinasas - Google Patents

Compuesto de pirimidina como inhibidor de jak quinasas

Info

Publication number
AR113803A1
AR113803A1 ARP180103131A ARP180103131A AR113803A1 AR 113803 A1 AR113803 A1 AR 113803A1 AR P180103131 A ARP180103131 A AR P180103131A AR P180103131 A ARP180103131 A AR P180103131A AR 113803 A1 AR113803 A1 AR 113803A1
Authority
AR
Argentina
Prior art keywords
compound
inhibitor
jak kinases
pyrimidine compound
formula
Prior art date
Application number
ARP180103131A
Other languages
English (en)
Inventor
Jerry Nzerem
Marta Dabros
Robert Murray Mkinnell
Gary E L Brandt
Ryan Hudson
Jennifer Kozak
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of AR113803A1 publication Critical patent/AR113803A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente provee un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, que es un inhibidor de las JAK quinasas. La presente también provee composiciones farmacéuticas que comprenden dicho compuesto, una forma cristalina, métodos de uso de dicho compuesto para tratar enfermedades inflamatorias de la piel y otras enfermedades y procesos e intermediarios útiles para preparar dicho compuesto. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1) o una sal farmacéuticamente aceptable del mismo.
ARP180103131A 2017-10-27 2018-10-26 Compuesto de pirimidina como inhibidor de jak quinasas AR113803A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27

Publications (1)

Publication Number Publication Date
AR113803A1 true AR113803A1 (es) 2020-06-10

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103131A AR113803A1 (es) 2017-10-27 2018-10-26 Compuesto de pirimidina como inhibidor de jak quinasas

Country Status (37)

Country Link
US (6) US10308646B2 (es)
EP (1) EP3672965B1 (es)
JP (1) JP7218364B2 (es)
KR (1) KR102613503B1 (es)
CN (1) CN111247142B (es)
AR (1) AR113803A1 (es)
AU (1) AU2018354370B2 (es)
BR (1) BR112020008015A2 (es)
CA (1) CA3074034A1 (es)
CL (1) CL2020001090A1 (es)
CR (1) CR20200180A (es)
CU (1) CU24671B1 (es)
DK (1) DK3672965T3 (es)
DO (1) DOP2020000083A (es)
EA (1) EA202091016A1 (es)
EC (1) ECSP20023795A (es)
ES (1) ES2932526T3 (es)
GE (1) GEP20227344B (es)
HR (1) HRP20221221T1 (es)
HU (1) HUE060401T2 (es)
IL (1) IL274037B2 (es)
LT (1) LT3672965T (es)
MA (1) MA49956B1 (es)
MD (1) MD3672965T2 (es)
MX (1) MX2020004255A (es)
NI (1) NI202000032A (es)
PE (1) PE20201495A1 (es)
PH (1) PH12020500528A1 (es)
PL (1) PL3672965T3 (es)
PT (1) PT3672965T (es)
RS (1) RS63608B1 (es)
SG (1) SG11202001706RA (es)
SI (1) SI3672965T1 (es)
TW (1) TWI789446B (es)
UA (1) UA125130C2 (es)
WO (1) WO2019084383A1 (es)
ZA (1) ZA202001641B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102613503B1 (ko) 2017-10-27 2023-12-13 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나제 저해제로서 피리미딘 화합물
JP2022510980A (ja) * 2018-11-30 2022-01-28 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ヘテロ芳香族誘導体調節因子、その製造方法及び使用
AR118768A1 (es) 2019-04-24 2021-10-27 Theravance Biopharma R&D Ip Llc Derivados de pirimidina como inhibidores de las cinasas jak
EP3959213A1 (en) 2019-04-24 2022-03-02 Theravance Biopharma R&D IP, LLC Pyrimidine jak inhibitors for the treatment of skin diseases
AU2021318201A1 (en) * 2020-07-28 2023-02-02 Arcutis Biotherapeutics, Inc. Topical formulation containing jak inhibitor and laureth-4
IL300906A (en) * 2020-08-26 2023-04-01 Nalo Therapeutics Modulators of MYC family proto-oncogene proteins
EP4225438A1 (en) * 2020-10-08 2023-08-16 Icahn School of Medicine at Mount Sinai Compositions for treatment alopecia areata, biomarkers for treatment success, and methods of use thereof
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2422371C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20030105090A1 (en) 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
EP1831216A2 (en) * 2004-12-23 2007-09-12 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
CN101360740A (zh) 2005-11-16 2009-02-04 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶
EP2044063A1 (en) 2006-06-30 2009-04-08 Astra Zeneca AB Pyrimidine derivatives useful in the treatment of cancer
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
BR112014015549A8 (pt) 2011-12-22 2017-07-04 Hoffmann La Roche composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (es) * 2014-08-21 2018-03-31
CN106687467A (zh) * 2014-09-30 2017-05-17 韩美精密化学株式会社 高纯度（r）‑9‑[2‑（磷酰甲氧基）丙基]腺嘌呤的制备方法
EP3303348B1 (en) * 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
EP3347097B1 (en) * 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
KR102244257B1 (ko) 2016-04-28 2021-04-26 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나제 저해제로서 피리미딘 화합물
KR102613503B1 (ko) * 2017-10-27 2023-12-13 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나제 저해제로서 피리미딘 화합물
AR118768A1 (es) 2019-04-24 2021-10-27 Theravance Biopharma R&D Ip Llc Derivados de pirimidina como inhibidores de las cinasas jak
EP3959213A1 (en) 2019-04-24 2022-03-02 Theravance Biopharma R&D IP, LLC Pyrimidine jak inhibitors for the treatment of skin diseases

Also Published As

Publication number Publication date
MA49956B1 (fr) 2022-11-30
JP7218364B2 (ja) 2023-02-06
US10562894B2 (en) 2020-02-18
SI3672965T1 (sl) 2022-11-30
CU20200053A7 (es) 2021-03-11
PL3672965T3 (pl) 2023-01-16
US11420965B2 (en) 2022-08-23
US10988470B2 (en) 2021-04-27
MD3672965T2 (ro) 2022-12-31
CR20200180A (es) 2020-08-12
HRP20221221T1 (hr) 2022-12-09
DK3672965T3 (da) 2022-10-03
GEP20227344B (en) 2022-01-25
TWI789446B (zh) 2023-01-11
SG11202001706RA (en) 2020-03-30
UA125130C2 (uk) 2022-01-12
ZA202001641B (en) 2021-04-28
KR102613503B1 (ko) 2023-12-13
CN111247142B (zh) 2022-12-02
CA3074034A1 (en) 2019-05-02
IL274037A (en) 2020-06-30
PT3672965T (pt) 2022-09-29
US20190127364A1 (en) 2019-05-02
JP2021501151A (ja) 2021-01-14
LT3672965T (lt) 2022-10-10
US10774080B2 (en) 2020-09-15
KR20200078517A (ko) 2020-07-01
NI202000032A (es) 2020-10-09
US20200140430A1 (en) 2020-05-07
US20220396573A1 (en) 2022-12-15
EP3672965B1 (en) 2022-09-07
US20210214349A1 (en) 2021-07-15
RS63608B1 (sr) 2022-10-31
EA202091016A1 (ru) 2020-07-17
US20200369660A1 (en) 2020-11-26
US20190241555A1 (en) 2019-08-08
AU2018354370B2 (en) 2023-04-27
AU2018354370A1 (en) 2020-04-09
BR112020008015A2 (pt) 2020-10-27
MA49956A (fr) 2020-07-01
DOP2020000083A (es) 2020-08-15
US11814377B2 (en) 2023-11-14
CU24671B1 (es) 2023-07-12
WO2019084383A1 (en) 2019-05-02
EP3672965A1 (en) 2020-07-01
PH12020500528A1 (en) 2021-06-07
IL274037B1 (en) 2023-07-01
ES2932526T3 (es) 2023-01-20
IL274037B2 (en) 2023-11-01
TW201930304A (zh) 2019-08-01
CN111247142A (zh) 2020-06-05
US10308646B2 (en) 2019-06-04
CL2020001090A1 (es) 2020-08-21
ECSP20023795A (es) 2020-06-30
HUE060401T2 (hu) 2023-02-28
PE20201495A1 (es) 2020-12-29
MX2020004255A (es) 2020-07-29

Similar Documents

Publication Publication Date Title
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CL2017002650A1 (es) Compuestos novedosos
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
GT201600123A (es) Inhibidores de syk
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CR20190156A (es) Derivados de bipirazol como inhibidores jak
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
EA201791576A1 (ru) Ингибитор jak
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CO2020000371A2 (es) Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CO2019008110A2 (es) Activador de nrf2